Lung Cancer Epidemiology in Korea

Shin, Aesun; Oh, Chang‐Mo; Kim, Byung Woo; Woo, Hyekyung; Won, Young Joo; Lee, Jin Soo

doi:10.4143/crt.2016.178

Cited by 52 publications

(52 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The corresponding 5-year survival rates were 24.73 ± 0.75% and 8.13 ± 0.30%, respectively. These ndings were comparable with those for patients with LD-SCLC and ED-SCLC in recent studies [2,16,17]. Thus, our operational criteria were considered to be acceptable.…”

Section: Study Design and Populationsupporting

confidence: 85%

Efficacy of definite concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study

Kim

Hong

Sung

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Small-cell lung cancer (SCLC) is a highly proliferative, rapidly growing tumor with a poor prognosis, even in cases of limited disease (LD). Timely and accurate high-intensity therapy is necessary. For concurrent chemoradiotherapy (CCRT), etoposide/platinum (EP)-based regimens are recommended, although irinotecan/platinum (IP)-based regimens are also effective with radiotherapy. This large-scale, retrospective, nationwide cohort study aimed to analyze the efficacy of CCRT in patients with LD-SCLC. Methods: Population data registered between January 2008 and December 2018 was extracted from the Health Insurance Review and Assessment Service of Korea database. Survival outcomes of 4,446 LD-SCLC patients who received CCRT were analyzed. Results: Patients who received EP-CCRT (n = 4,187) showed better progression-free survival (PFS: 11.2 months) and overall survival (OS: 22.2 months) than those who received IP-CCRT (n = 259; PFS: 9.6 months, P = 0.0477; OS: 16.4 months, P <0.0001). When CCRT failed, dual-agent chemotherapy (n = 925; OS: 9.1 months) provided a better survival benefit than single-agent chemotherapy (n = 815; OS: 7.5 months). IP-based chemotherapy resulted in better OS (9.6 months) than EP-based chemotherapy (7.1 months, P = 0.017) in platinum-resistant relapsed patients; the opposite was observed for platinum-sensitive relapsed patients (OS: EP, 17.2 months; IP, 6.6 months; P <0.0001). Poisson regression analysis demonstrated that age, EP-CCRT, and hypercholesterolemia retained significant associations with OS after adjustment for all variables. Conclusion: In the Korean population, the effects of EP-CCRT on OS and PFS are significantly more favorable than those of IP-CCRT.

show abstract

Section: Study Design and Populationsupporting

confidence: 85%

Efficacy of definite concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study

Kim

Hong

Sung

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Traditional biopsy from the primary tumor site has limitations due to its invasive nature [ 1 ]. In particular, in lung cancer, which is among the leading causes of cancer-related death worldwide, obtaining a tumor tissue sample in the thoracic cavity to guide treatment decisions is challenging [ 2 , 3 ]. Therefore, there is a high demand for continuous monitoring through detectable tumor surrogate specimens in blood with sensitive molecular biology techniques [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer

et al. 2017

View full text Add to dashboard Cite

We used computed tomography (CT) to explore the prognostic value of cell-free (cf) DNA quantification and its predictive efficacy over time after chemotherapy in non-small-cell lung cancer (NSCLC) patients. In total, 177 NSCLC patients were enrolled in a prospective biomarker trial. Consecutive paired blood collection was performed to determine cfDNA concentrations at baseline CT and throughout serial follow-ups. The best cfDNA cut-off value to predict progression-free and overall survival was determined using X-tile analysis. Among 112 chemo-naive patients with stage IV adenocarcinoma, 43 were available for follow-up analysis. Cox regression multivariate analysis indicated that a high cfDNA concentration was an independent negative prognostic factor for progression-free survival (hazard ratio: 2.60; 95% confidence interval: 1.65-4.10; p = 0.008) and overall survival (hazard ratio: 2.63; 95% confidence interval: 1.66-4.17; p < 0.001). However, cfDNA concentration changes during treatment did not correlate with radiological CT responses at first follow-up or best response. No pattern was noted in the percent change in the cfDNA concentration from baseline or subsequently measured level to progression. The serum cfDNA concentration is thus associated with NSCLC patient prognosis, but does not appear to be a clinically valid marker for tumor responses.

show abstract

“…1 In particular, non-small-cell lung cancer constitutes 85% of lung cancer cases and tends to develop resistance to chemotherapy. Thus, novel chemotherapeutic agents are needed to treat non-small-cell lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Improved chemotherapeutic efficacy of injectable chrysin encapsulated by copolymer nanoparticles

Kim¹,

Lim

Shim³

et al. 2017

IJN

View full text Add to dashboard Cite

Chrysin is a flavone that is found in several plants and in honeycomb and possesses various biological activities. However, its low solubility means it has poor bioavailability, which must be resolved to enable its pharmaceutical applications. In the present study, chrysin was incorporated into methoxy poly(ethylene glycol)-β-polycaprolactone nanoparticles (chrysin-NPs) using the oil-in-water technique in order to overcome problems associated with chrysin. The properties of chrysin-NPs were analyzed, and their anticancer effects were investigated in vitro and in vivo. Chrysin-NPs were 77 nm sized (as determined by dynamic laser light scattering) and showed a monodisperse distribution. The zeta potential of chrysin-NPs was −2.22 mV, and they were spherically shaped by cryo-transmission electron microscopy (cryo-TEM). The loading efficiency of chrysin-NPs was 46.96%. Chrysin-NPs retained the cytotoxicity of chrysin in A549 cells. The therapeutic efficacies of chrysin-NPs were compared with those of chrysin in an A549-derived xenograft mouse model. Chrysin-NPs were intravenously injected at a 10 times lower dosage than chrysin 3 times per week (q2d×3/week). However, free chrysin was orally administrated 5 times per week (q1d×5/week). Chrysin-NP-treated group showed significant tumor growth delay, which was similar to that of chrysin-treated group, despite the considerably lower total dosage. These results suggest that the injectable chrysin-NPs enhance therapeutic efficacy in vivo and offer a beneficial formulation for chemotherapy.

show abstract

Lung Cancer Epidemiology in Korea

Cited by 52 publications

References 22 publications

Efficacy of definite concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study

Efficacy of definite concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study

Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer

Improved chemotherapeutic efficacy of injectable chrysin encapsulated by copolymer nanoparticles

Contact Info

Product

Resources

About